BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33824293)

  • 21. PF-06409577 Activates AMPK Signaling and Inhibits Osteosarcoma Cell Growth.
    Zhu YR; Zhang XY; Wu QP; Yu CJ; Liu YY; Zhang YQ
    Front Oncol; 2021; 11():659181. PubMed ID: 34336655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.
    Storozhuk Y; Hopmans SN; Sanli T; Barron C; Tsiani E; Cutz JC; Pond G; Wright J; Singh G; Tsakiridis T
    Br J Cancer; 2013 May; 108(10):2021-32. PubMed ID: 23632475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway.
    Wei C; Yao X; Jiang Z; Wang Y; Zhang D; Chen X; Fan X; Xie C; Cheng J; Fu J; Leung EL
    Pharmacol Res; 2019 Jun; 144():79-89. PubMed ID: 30974169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
    Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway.
    Wang WJ; Mao LF; Lai HL; Wang YW; Jiang ZB; Li W; Huang JM; Xie YJ; Xu C; Liu P; Li YM; Leung ELH; Yao XJ
    Pharmacol Res; 2020 Nov; 161():105129. PubMed ID: 32783976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
    Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 28. Compound 13, an α1-selective small molecule activator of AMPK, potently inhibits melanoma cell proliferation.
    Hu X; Jiang F; Bao Q; Qian H; Fang Q; Shao Z
    Tumour Biol; 2016 Jan; 37(1):1071-8. PubMed ID: 26271666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
    Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
    Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
    Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J
    Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. R2-8018 reduces the proliferation and migration of non-small cell lung cancer cells by disturbing transactivation between M3R and EGFR.
    Lan L; Wang H; Yang R; Liu F; Bi Q; Wang S; Wei X; Yan H; Su R
    Life Sci; 2019 Oct; 234():116742. PubMed ID: 31401315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antrodin C, an NADPH Dependent Metabolism, Encourages Crosstalk between Autophagy and Apoptosis in Lung Carcinoma Cells by Use of an AMPK Inhibition-Independent Blockade of the Akt/mTOR Pathway.
    Yang H; Bai X; Zhang H; Zhang J; Wu Y; Tang C; Liu Y; Yang Y; Liu Z; Jia W; Wang W
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30870998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 34. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
    Venkatesha VA; Joshi A; Venkataraman M; Sonawane V; Bhatia D; Tannu P; Bose J; Choudhari S; Srivastava A; Pandey PK; Lad VJ; Sangana R; Ahmed T; Damre A; Deore V; Sahu B; Kumar S; Sharma S; Agarwal VR
    Mol Cancer; 2014 Dec; 13():259. PubMed ID: 25466244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AMPK activation by GSK621 inhibits human melanoma cells in vitro and in vivo.
    Chen L; Chen Q; Deng G; Kuang S; Lian J; Wang M; Zhu H
    Biochem Biophys Res Commun; 2016 Nov; 480(4):515-521. PubMed ID: 27751856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
    Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
    Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phillygenin regulates proliferation and apoptosis of non-small cell lung cancer through by AMPK/ERK/NF-κB axis.
    Wu S; Zhang Y; Zhang Y; Chen L; Xu X; Dang Y; Ti X
    Pharmazie; 2020 Oct; 75(10):512-515. PubMed ID: 33305728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
    Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
    Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
    Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L
    Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.